Efficacy and safety of Privigen^®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura

References

• Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 2006; 43(3 Suppl 5): S3—S10.
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current con-cepts in pathophysiology and management. Thromb Haemost 2008; 99(1): 4–13.
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. NEngl J Med 2002; 346(13): 995–1008.
   PubMed Web of Science ®Google Scholar
• Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologiea 2005; 90(6): 829–832.
   PubMed Web of Science ®Google Scholar
• George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocy-topenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88(1): 3–40.
   PubMed Web of Science ®Google Scholar
• Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120(4): 574–596.
   PubMed Web of Science ®Google Scholar
• Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Hely Paediatr Acta 1981; 36(1): 81–86.
   PubMedGoogle Scholar
• Wolf HH, Davies SV, Borte M et al. Efficacy, tolerability, safetyand pharmacokinetics of a nanofiltered intravenous immunoglo-bulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003; 84(1): 45–53.
   PubMed Web of Science ®Google Scholar
• Colovic M, Dimitrijevic M, Sonnenburg C, Suvajdzic N, Donfrid M, Bogdanovic A. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J2003; 4(5): 358–362.
   Google Scholar
• Bussel JB, Eldor A, Kelton JG et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004; 91(4): 771–778.
   PubMed Web of Science ®Google Scholar
• Bierling P, Godeau B. Intravenous immunoglobulin for auto-immune thrombocytopenic purpura. Hum Immunol 2005; 66(4): 387–394.
   PubMed Web of Science ®Google Scholar
• Kurlander R, Coleman RE, Moore J, Gockerman J, Rosse W, Siegal R. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. Am J Med 1987; 83(4A): 17–24.
   PubMed Web of Science ®Google Scholar
• Schnorf J, Arnet B, Burek-Kozlowska A et al. Laboratory parameters measured during infusion of immunoglobulin prepara-tions for intravenous use and related to tolerability. In: Kazatchkine MD, More11 A (eds). Intravenous immunoglobulin research and therapy. New York, London: The Parthenon Publishing Group, 1996; 312–313.
   Google Scholar
• Bolli R, Spycher MO, Briigger R, Wiist B, Gennari K. IgG-dimer formation in liquid immunoglobulin preparations is inhibited by nicotinamide and other amphiphilic compounds. J Autoimmun 1999; (Suppl 1): 96.
   Google Scholar
• Kempf C, Stucki M, Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 2007; 35(1): 35–42.
   PubMed Web of Science ®Google Scholar
• Stucki M, Boschetti N, Schaefer W et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008; 36(4): 239–247.
   PubMed Web of Science ®Google Scholar
• Druml W, Heinzel G, Kleinberger G. Amino acid kinetics in patients with sepsis. Am J Clin Nutr 2001; 73(5): 908–913.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN et al. AMG 531, a thrombopoi-esis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355(16): 1672–1681.
   PubMed Web of Science ®Google Scholar
• Brenner B. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin. Clin Exp Rheumatol 1996; 14(Suppl 15): S115–5119.
   PubMedGoogle Scholar
• Tarantino MD, Young G, Bertolone Si et al. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 2006; 148(4): 489–494.
   PubMed Web of Science ®Google Scholar
• Newland AC, Burton I, Cavenagh JD et al. Vigam-S, a solvent/ detergent-treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura. Transfus Med 2001; 11(1): 37–44.
   PubMed Web of Science ®Google Scholar
• Scribner CL, Kapit RM, Phillips ET, Rickles NM. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994; 121(4): 305–306.
   PubMed Web of Science ®Google Scholar
• Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121(4): 259–262.
   PubMed Web of Science ®Google Scholar
• Al-Ghamdi H, Mustafa MM, Al-Fawaz I, Al-Dowaish A. Acute aseptic meningitis associated with administration of immunoglo-bulin in children: a case report and review of the literature. Ann Saudi Med 1999; 19(4): 362–364.
   PubMed Web of Science ®Google Scholar
• Copelan EA, Strohm PL, Kennedy MS, Tutschka Pi. Hemolysis following intravenous immune globulin therapy. Transfusion 1986; 26(5): 410–412.
   PubMed Web of Science ®Google Scholar
• Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J. Hemolysis after high-dose intravenous Ig. Blood 1993; 82(12): 3789.
   PubMed Web of Science ®Google Scholar
• Daw Z, Padmore R, Neurath D et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48(8): 1598–1601.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106(7): 2244–2251.
   PubMed Web of Science ®Google Scholar
• George JN, Raskob GE, Vesely SK et al. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 2003; 74(3): 161–169.
   PubMed Web of Science ®Google Scholar
• Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112(4): 1076–1078.
   PubMed Web of Science ®Google Scholar
• Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and devel-opment factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100(2): 728–730.
   PubMed Web of Science ®Google Scholar
• Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003; 28(3): 249–255.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204(1): 11–15.
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345(10): 747–755.
   PubMed Web of Science ®Google Scholar
• Semple JW, Miley Y, Cosgrave D et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocyto-penic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87(10): 4245–4254.
   PubMed Web of Science ®Google Scholar
• Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 2003; 92(6): 1206–1215.
   PubMed Web of Science ®Google Scholar